Post
Risk adjusted net present value: What is the current valuation of Legend Biotech’s LB-1908?
LB-1908 is a gene-modified cell therapy commercialized by Legend Biotech, with a leading Phase I program in Adenocarcinoma Of The …
Risk adjusted net present value: What is the current valuation of Celltrion’s Tocilizumab biosimilar?
Tocilizumab biosimilar is a monoclonal antibody commercialized by Celltrion, with a leading Phase III program in Rheumatoid Arthritis. According to …
Risk adjusted net present value: What is the current valuation of AstraZeneca’s Puxitatug Samrotecan?
Puxitatug Samrotecan is a monoclonal antibody conjugated commercialized by AstraZeneca, with a leading Phase II program in Metastatic Bile Duct …
Risk adjusted net present value: What is the current valuation of Amgen’s Ustekinumab Biosimilar?
Ustekinumab Biosimilar is a monoclonal antibody commercialized by Amgen, with a leading Phase III program in Plaque Psoriasis (Psoriasis Vulgaris). …
Risk adjusted net present value: What is the current valuation of Gracell Biotechnologies’s GC-012F?
GC-012F is a gene-modified cell therapy commercialized by Gracell Biotechnologies, with a leading Phase II program in Relapsed Multiple Myeloma. …
IL2-CD25 by Bristol-Myers Squibb for Systemic Lupus Erythematosus: Likelihood of Approval
IL2-CD25 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, …
SLATE-001 by Gritstone Bio for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
SLATE-001 is under clinical development by Gritstone Bio and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, …
PXS-5505A by Pharmaxis for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
PXS-5505A is under clinical development by Pharmaxis and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase …
Gamcemetinib by Bristol-Myers Squibb for Inflammation: Likelihood of Approval
Gamcemetinib is under clinical development by Bristol-Myers Squibb and currently in Phase I for Inflammation. According to GlobalData, Phase I …
Gamcemetinib by Bristol-Myers Squibb for Autoimmune Disorders: Likelihood of Approval
Gamcemetinib is under clinical development by Bristol-Myers Squibb and currently in Phase I for Autoimmune Disorders. According to GlobalData, Phase …
DS-3939 by Glycotope for Metastatic Biliary Tract Cancer: Likelihood of Approval
DS-3939 is under clinical development by Glycotope and currently in Phase II for Metastatic Biliary Tract Cancer. According to GlobalData, …
DS-3939 by Glycotope for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
DS-3939 is under clinical development by Glycotope and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer. According to …
DS-3939 by Glycotope for Metastatic Ovarian Cancer: Likelihood of Approval
DS-3939 is under clinical development by Glycotope and currently in Phase II for Metastatic Ovarian Cancer. According to GlobalData, Phase …
Canakinumab by Novartis for Sickle Cell Disease: Likelihood of Approval
Canakinumab is under clinical development by Novartis and currently in Phase II for Sickle Cell Disease. According to GlobalData, Phase …
DS-3939 by Glycotope for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
DS-3939 is under clinical development by Glycotope and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase …